GlassScriptPhysician profile
Christy Holmes
NPI 1134723802
$2,573.23
in general payments reported to CMS, 2019-2025
28 companies · $546 in 2025
The $546 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $278 · 2022: $680 · 2023: $420 · 2024: $650 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,615.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $620.13 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $287.62 | 2022-2025 | Caplyta |
| Corium, LLC | $250.91 | 2022-2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $198.97 | 2023-2025 | Uzedy, Austedo |
| Neurocrine Biosciences, INC. | $176.05 | 2022-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $137.48 | 2021-2025 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $115.20 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $105.45 | 2022-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $81.28 | 2023-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $67.59 | 2024-2025 | Cobenfy |
| Boston Scientific Corporation | $57.32 | 2022-2023 | Wavewriter Alpha Prime 16 |
| Biohaven Pharmaceuticals, INC. | $54.49 | 2021 | |
| Scilex Pharmaceuticals INC. | $52.54 | 2021-2022 | |
| Forte Bio-Pharma LLC | $47.32 | 2021 | |
| Eisai INC. | $38.13 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $33.61 | 2021-2022 | |
| Braeburn INC. | $27.55 | 2024 | Brixadi |
| Luye Pharma (USA) LTD. | $24.45 | 2025 | Erzofri Extended-Release |
| Uswm, LLC | $23.79 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.70 | 2022 | |
| Vertos Medical, INC. | $22.37 | 2022 | |
| Upsher-Smith Laboratories LLC | $21.38 | 2021 | |
| Neurelis, INC. | $20.47 | 2022 | |
| Lundbeck LLC | $20.07 | 2021 | |
| Vanda Pharmaceuticals INC. | $19.44 | 2025 | Hetlioz, Fanapt |
| Emd Serono, INC. | $17.27 | 2021 | |
| Axsome Therapeutics, INC. | $15.55 | 2024 | Auvelity |
| Arbor Pharmaceuticals, INC. | $13.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christy Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.